RxDoctor Payments Data

Francisco Dieguez, MD

Interventional Cardiology · Hialeah, FLNPI 1013053859

Payments from drug & device makers

$172,207in general payments, 2019–2025

Across 517 payments — averaging $333.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$99K
  • Angiodynamics, Inc.$40K
  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$17K
  • Medtronic$3K
  • Bard Peripheral Vascular, Inc.$3K
  • Abbott$2K
  • plus $9K from 38 others
$64,875in research payments, 2019–2025

Across 3 payments — averaging $21,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$65K

What the payments were for

  • Travel & lodging$8181%
  • Food & beverage$17,27729%
  • Education$920%
  • Other$41,68870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$172,207 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,681,481
Medicare patients
384
Services billed
2,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban503$322,470
EliquisApixaban382$245,431
EntrestoSacubitril/Valsartan280$209,056
BrilintaTicagrelor137$69,831
FarxigaDapagliflozin Propanediol96$59,784
Repatha SureclickEvolocumab54$45,908
Ranolazine ErRanolazine245$20,738
VerquvoVericiguat30$19,416
ClopidogrelClopidogrel Bisulfate1,772$11,151
MultaqDronedarone Hcl12$9,661
DapagliflozinDapagliflozin Propanediol18$8,724
JardianceEmpagliflozin12$6,886
Metoprolol Succinate733$5,289
Nifedipine ErNifedipine266$4,841
Atorvastatin Calcium643$4,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,052$322,470503 claims
PfizerEliquis$692$245,431382 claims
NovartisEntresto$98,590$209,056280 claims
AstraZenecaBrilinta, Farxiga$368$129,615233 claims
MerckVerquvo$461$19,41630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →